Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 8/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.56 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.51 |
| ▸ | MTR | Q99707 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.50 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904904 | 0.86 | ADRA1A (0.66) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL1855782 | 0.83 | ADRA1D (0.58) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL27048956 | 0.83 | ADRA1D (0.60) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL1858158 | 0.78 | OPRM1 (0.60) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL22605448 | 0.78 | ADRA1D (0.57) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL1858543 | 0.76 | DRD2 (0.51) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL6214279 | 0.75 | CHRM4 (0.44) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL1862937 | 0.75 | CHRM4 (0.56) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL904853 | 0.74 | CCR3 (0.55) | ADRA1DADRA1AADRA1BHTR2AHTR7 | |
| SCHEMBL13801284 | 0.74 | CHRM4 (0.52) | ADRA1DADRA1AADRA1BHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | claimed |
| EP-1930322-A1 | 1-(4-piperidinyl)-1,3-dihydro-2H-benzoxazole-2-one derivatives and related compounds as nociceptin analogs and ORL1 ligands for the treatment of pain | EURO-CELTIQUE S.A. (LU) | 2008-06-11 | — | — | EP | claimed |
| EP-1598340-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-BENZOXAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | claimed |
| EP-1379246-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-09-28 | — | — | EP | claimed |
| EP-1379246-A1 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | claimed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | claimed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| US-8252815-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | PURDUE PHARMA L.P. (US) | 2012-04-19 | — | — | US | disclosed |
| US-7939670-B2 | Nociceptin analogs | PURDUE PHARMA L.P. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-1598338-B9 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-11-18 | — | — | EP | disclosed |
| EP-1598339-B1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156640-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE S.A. | 2009-06-18 | — | — | US | disclosed |
| EP-1598338-A1 | 1-(4-PIPERIDINYL)-1,3-DIHYDRO-2H-INDOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO-CELTIQUE S.A. (LU) | 2005-11-23 | — | — | EP | disclosed |
| EP-1379246-A4 | NOCICEPTIN ANALOGS | EURO CELTIQUE SA (LU) | 2005-09-28 | — | — | EP | disclosed |
| US-20050159452-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2005-07-21 | — | — | US | disclosed |
| US-6867222-B2 | Nociceptin analogs | EURO-CELTIQUE, S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| EP-1379246-A1 | NOCICEPTIN ANALOGS | Euro-Celtique S.A. (LU) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069249-A1 | Nociceptin analogs | PURDUE PHARMA L.P. | 2003-04-10 | — | — | US | disclosed |
| WO-2002085357-A1 | NOCICEPTIN ANALOGS | EURO-CELTIQUE, S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156640-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | ADRA1D 182/4885ADRA1A 116/4885ADRA1B 82/4885 |
| US-20120095049-A1 | NOCICEPTIN ANALOGS | OPRL1, NPY1R, NPBWR1 | ADRA1D 182/4885ADRA1A 116/4885ADRA1B 82/4885 |
| US-20030069249-A1 | Nociceptin analogs | OPRL1, NPY1R, OPRK1 | ADRA1D 108/4885ADRA1A 85/4885ADRA1B 54/4885 |
| US-20050159452-A1 | Nociceptin analogs | OPRL1, NPY1R, NPBWR1 | ADRA1D 182/4885ADRA1A 116/4885ADRA1B 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.